Can Oral Gildeuretinol Slow Advanced Macular Degeneration? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.

  • By

  • Andrea Surnit

  • July 20, 2026

  • 3 min

Share

  • 1

    Oral gildeuretinol acetate did not significantly slow geographic atrophy progression compared to placebo in age-related macular degeneration patients.

  • 2

    The phase 2/3 SAGA trial involved 198 patients aged 60 and older, assigned to receive either gildeuretinol or placebo for 24 months.

  • 3

    Geographic atrophy lesion growth was reduced by 13% with gildeuretinol, but this difference was not statistically significant.

  • 4

    Secondary outcomes showed exploratory benefits for gildeuretinol, including less decline in low-luminance visual acuity and improved quality of life.

  • 5

    The study's primary endpoint was not met, and researchers emphasized that secondary findings are exploratory and require further investigation.

Original Source(s)

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

  • by Andrea Surnit

  • July 20, 2026

Related Content

Myopia Severity Tied to Pediatric Retinal Pathology

Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia

2026 Retina World Congress Preview

Baruch D. Kuppermann, MD, PhD, highlights the global focus and broad retina agenda of the upcoming Retina World Congress meeting in Fort Lauderdale.

The Retina’s Lost Lipid Signal

High-resolution metabolomics identifies erucamide depletion in retinal degeneration and links restoration to neurovascular rescue

  • June 30, 2026

  • 2 min